We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amid what appears to be a deteriorating outlook for patent and bioequivalence rules, Indian generics firms are looking to Brazil's drug market, largely in order to escape competitive pressures at home.
New Russian government regulations limiting subsidies on drugs only to companies which manufacture in the country -- set to be introduced in December -- pose a new challenge for foreign firms.
Strong growth from its Adderall XR attention disorder treatment helped Shire Pharmaceuticals lift second quarter profits by 25% and up its estimate of revenue growth for the year as a whole.
SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceutical and non-pharmaceutical products, today announced its 2005 second quarter operational and financial results.
Solvay announced today that it has completed the acquisition of 100% of Fournier Pharma, following the successful completion of social and regulatory procedures worldwide.
Nihon Pharmaceutical Industry (NPI), the Japanese joint venture company of Ranbaxy Laboratories, has launched its first collaborative research product --Vogseal in Japan. NPI is a venture between Ranbaxy and Nippon Chemiphar.
Takeda Pharmaceutical Co, Japan's largest drug maker, will partly outsource its sales of Roserem, a new insomnia treatment to be launched in the US in September, the Nihon Keizai Shimbun reported, citing unnamed company officials.
Biotechnology company Millennium Pharmaceuticals Inc. (MLNM.O: Quote, Profile, Research) on Thursday said its quarterly loss narrowed on lower costs and higher sales of its bone cancer drug Velcade.